Keymed Biosciences Inc. (HKG:2162)

Hong Kong · Delayed Price · Currency is HKD

78.90

-1.80 (-2.23%)

Apr 17, 2026, 3:45 PM HKT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
R&D and Commercialisation of Pharmaceutical Products	716.31M	428.12M	354.10M	100.06M	110.27M
R&D and Commercialisation of Pharmaceutical Products Growth	67.31%	20.91%	253.87%	-9.26%	-
Total	716.31M	428.12M	354.10M	100.06M	110.27M
Total Growth	67.31%	20.91%	253.87%	-9.26%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
United States of America	393.67M	-	-	-	-
Mainland China	322.17M	36.97M	903.00K	100.06M	110.27M
Mainland China Growth	771.35%	3994.57%	-99.10%	-9.26%	-
United Kingdom	474.00K	-	-	-	-
Overseas	-	391.15M	353.19M	-	-
Overseas Growth	-	10.75%	-	-	-
Total	716.31M	428.12M	354.10M	100.06M	110.27M
Total Growth	67.31%	20.91%	253.87%	-9.26%	-

Source: S&P Global Market Intelligence.